Master Specimen Tracking in Adolescent Master Protocol, PH200

Master Specimen Tracking (July 2024). Data updated in 2024 in DASH to include the follow-up time points through the final participant visit in 2020.
Study Description
The PHACS AMP study is designed to define the impact of HIV infection and antiretroviral therapy on pre-adolescents and adolescents with perinatal HIV infection. Domains investigated include growth and sexual maturation; metabolic risk factors for cardiovascular disease; cardiac function; bone health; neurologic, neurodevelopment, language, hearing, and behavioral function; and adolescent gynecology and HPV infection. Biospecimens are available. AMP includes 451 perinatally HIV-infected (PHIV) youth and 227 perinatally HIV-exposed uninfected (PHEU) youth, age 6 to 17 years at study entry. [587 caregivers also enrolled to provide information on their children.]